Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Risperidone is an atypical antipsychotic agent that displays 5-HT2A receptor antagonism. Also displays high affinity at D2 receptors (Ki values are 0.4 and 3.13 nM for 5-HT2A and D2 receptors respectively).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 410.48. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||24.36 mL||121.81 mL||243.62 mL|
|0.5 mM||4.87 mL||24.36 mL||48.72 mL|
|1 mM||2.44 mL||12.18 mL||24.36 mL|
|5 mM||0.49 mL||2.44 mL||4.87 mL|
References are publications that support the biological activity of the product.
Leysen et al (1988) Biochemical profile of risperidone, a new antipsychotic. J.Pharmacol.Exp.Ther. 247 661 PMID: 2460616
Leysen et al (1994) Risperidone: a novel antipsychotic with balanced serotonin-DA antagonism, receptor occupancy profile, and pharmacologic activity. J.Clin.Psychiatry 55 5 PMID: 7520908
Stathis et al (1996) Risperidone: a novel antipsychotic with many "atypical" properties. Psychopharmacol. 127 181
Wang et al (2018) Structure of the D2 DA receptor bound to the atypical antipsychotic drug risperidone Nature 555 269 PMID: 29466326
If you know of a relevant reference for Risperidone, please let us know.
Keywords: Risperidone, Risperidone supplier, 5-HT2A, antagonists, D2, Serotonin, Receptors, Dopamine, dopaminergic, R64766, R, 64, 766, 2865, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Risperidone include:
Kurita et al (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15 1245 PMID: 22864611
Canfrán-Duque et al (2015) Curcumin Mitigates the Intracellular Lipid Deposit Induced by Antipsychotics In Vitro. Sci Rep 10 e0141829 PMID: 26517556
Do you know of a great paper that uses Risperidone from Tocris? Please let us know.
Average Rating: 4 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
We found that risperidone treatment decreased hyperactivity of NF-kappa B p50 subunit KO mice, but had no effect on defective social interaction. Altogether, these data add complexity to a growing body of data, suggesting a link between dysregulation of the NF-kappa B pathway and neurodevelopmental disorders pathogenesis.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.